Is RECEF or QYLD a better dividend investment in 2026?

RECEF currently yields 909.09% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: RECEF offers higher current income.

What is the dividend yield difference between RECEF and QYLD?

RECEF has a forward dividend yield of 909.09% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 897.17 percentage points.

Home › Compare › RECEF vs QYLD

RECEF vs QYLD: Dividend Comparison 2026

RECEF yields 909.09% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 RECEF wins by $8252648.18M in total portfolio value

INVESTMENT

TIME HORIZON10 years

RECEF

● Live price

909.09%

Share price

$0.22

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$8252648.21M

Annual income

$6,784,560,004,057.53

Full RECEF calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — RECEF vs QYLD

📍 RECEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	RECEF	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, RECEF + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

RECEF pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RECEF

Annual income on $10K today (after 15% tax)

$77,272.73/yr

After 10yr DRIP, annual income (after tax)

$5,766,876,003,448.90/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, RECEF beats the other by $5,766,875,998,638.49/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RECEF + QYLD for your $10,000?

RECEF: 50%QYLD: 50%

100% QYLD50/50100% RECEF

Portfolio after 10yr

$4126324.12M

Annual income

$3,392,280,004,858.43/yr

Blended yield

82.21%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RECEF buys

QYLD buys

Politician	Chamber	Ticker	Type	Amount	Date
Tim Moore	🏢 House	$QYLD	▼ Sell	$15,001 - $50,000	2025-05-02
Tim Moore	🏢 House	$QYLD	▲ Buy	$15,001 - $50,000	2025-04-07
Dwight Evans	🏢 House	$QYLD	▼ Sell	$1,001 - $15,000	2022-11-14
Dwight Evans	🏢 House	$QYLD	▼ Sell	$1,001 - $15,000	2020-10-29

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricRECEFQYLD

Forward yield	909.09% ✓	11.92%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$8252648.21M ✓	$25.4K
Annual income after 10y	$6,784,560,004,057.53 ✓	$5,659.31
Total dividends collected	$8138900.96M ✓	$27.1K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: RECEF vs QYLD ($10,000, DRIP)

Year	RECEF Portfolio	RECEF Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$101,609	$90,909.09	$10,352	$1,192.36	+$91.3K → RECEF
2	$972,011	$863,288.79	$10,830	$1,347.57	+$961.2K → RECEF
3	$8,758,157	$7,718,105.75	$11,460	$1,539.07	+$8.75M → RECEF
4	$74,364,546	$64,993,317.91	$12,275	$1,777.84	+$74.35M → RECEF
5	$595,318,755	$515,748,691.06	$13,323	$2,078.95	+$595.31M → RECEF
6	$4,495,664,203	$3,858,673,134.79	$14,667	$2,463.34	+$4495.65M → RECEF
7	$32,043,550,537	$27,233,189,840.42	$16,396	$2,960.57	+$32043.53M → RECEF
8	$215,696,715,677	$181,410,116,602.38	$18,631	$3,612.97	+$215696.70M → RECEF
9	$1,372,045,052,584	$1,141,249,566,809.58	$21,548	$4,482.15	+$1372045.03M → RECEF
10	$8,252,648,210,323	$6,784,560,004,057.53	$25,398	$5,659.31	+$8252648.18M → RECEF

RECEF vs QYLD: Complete Analysis 2026

RECEF — Stock

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Full RECEF Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this RECEF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RECEF vs SCHD RECEF vs JEPI RECEF vs O RECEF vs KO RECEF vs MAIN RECEF vs XYLD RECEF vs JEPQ RECEF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.